HomeCompareSDTHF vs MRK

SDTHF vs MRK: Dividend Comparison 2026

SDTHF yields 9.51% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SDTHF wins by $61.1K in total portfolio value
10 years
SDTHF
SDTHF
● Live price
9.51%
Share price
$21.02
Annual div
$2.00
5Y div CAGR
21%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$118.8K
Annual income
$29,169.11
Full SDTHF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — SDTHF vs MRK

📍 SDTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSDTHFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SDTHF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SDTHF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SDTHF
Annual income on $10K today (after 15% tax)
$808.75/yr
After 10yr DRIP, annual income (after tax)
$24,793.74/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, SDTHF beats the other by $16,197.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SDTHF + MRK for your $10,000?

SDTHF: 50%MRK: 50%
100% MRK50/50100% SDTHF
Portfolio after 10yr
$88.3K
Annual income
$19,641.44/yr
Blended yield
22.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SDTHF
No analyst data
Altman Z
1.6
Piotroski
3/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SDTHF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSDTHFMRK
Forward yield9.51%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR21%32.7%
Portfolio after 10y$118.8K$57.7K
Annual income after 10y$29,169.11$10,113.78
Total dividends collected$86.0K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SDTHF vs MRK ($10,000, DRIP)

YearSDTHF PortfolioSDTHF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,851$1,151.28$11,213$373.04+$638.00SDTHF
2$14,224$1,542.94$12,667$512.06+$1.6KSDTHF
3$17,314$2,094.12$14,439$708.14+$2.9KSDTHF
4$21,408$2,882.54$16,640$988.16+$4.8KSDTHF
5$26,937$4,030.58$19,432$1,394.07+$7.5KSDTHF
6$34,558$5,735.14$23,057$1,992.90+$11.5KSDTHF
7$45,297$8,320.33$27,889$2,894.79+$17.4KSDTHF
8$60,801$12,332.94$34,518$4,286.29+$26.3KSDTHF
9$83,777$18,720.05$43,912$6,494.35+$39.9KSDTHF
10$118,811$29,169.11$57,714$10,113.78+$61.1KSDTHF

SDTHF vs MRK: Complete Analysis 2026

SDTHFStock

Sdiptech AB (publ) provides technical products and services for infrastructures in Sweden, the United Kingdom, Germany, Croatia, Austria, Norway, Finland, and internationally. The company operates through three segments: Water & Energy, Special Infrastructure Solutions, and Property Technical Services. It engages in the service, renovation, modernization, and new construction, as well as renovation of roof. The company also provides water and sewage treatment, water systems, and water purification services; power supply, electrical automation, and temporary electricity services; air and climate control products and services to monitor and control indoor climate, air quality, and energy efficiency. In addition, it offers safety and security services for secure communication and integrated security systems in public and private environments; and digital technology for speed monitoring and infrastructure for air traffic communication. Sdiptech AB (publ) was founded in 2004 and is based in Stockholm, Sweden.

Full SDTHF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SDTHF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SDTHF vs SCHDSDTHF vs JEPISDTHF vs OSDTHF vs KOSDTHF vs MAINSDTHF vs JNJSDTHF vs ABBVSDTHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.